at 12 noon leading to a rise from 0-85 tLg/ml at 11.15 a.m. to 4-32 Fg/ml at 12.15 p.m. The second unusual feature is the high peak concentration of levodopa, 4-32 jig/ml. A third point of contrast is the prolonged plasma half life of levodopa in our patient, 1-57 hours compared with 1 08 hours.
Discussion
The "on-off" phenomenon has become recognized as a problem of increasing importance over the last year. Its relatively recent emergence can be explained in terms of prolonged periods of therapy usually completed before its appearance. Attacks are particularly distressing when, as often occurs, they develop in patients who had done well on levodopa. No satisfactory approach to their management has been reported.
The simplest explanation for a dramatic increase in hypokinesia in patients receiving levodopa would be inadequate intake or absorption of the drug. The findings reported here indicate that it is more likely that the attacks represent a toxic reaction to levodopa or one of its metabolites. This view would be consonant with the reported association of these hypokinetic episodes with certain known adverse reactions to levodopa such as confusion and hyperkinesia, which are also accompanied by high plasma concentrations of levodopa. Furthermore, the higher prevalence of "on-off" phenomena in patients who have been on treatment with high doses for prolonged periods is in accord with the view that a build-up of levodopa or one of its metabolites is responsible.
While the mechanism of levodopa toxicity in these episodes is not known, Hornykiewicz (1973) has made a suggestion, entirely compatible with our observations, that a metabolite of levodopa is acting as a "partial agonist" or "false transmitter" in the central nervous system.
One feature of interest in the patient studied here was the extremely rapid absorption of levodopa. As the plasma half life was prolonged, it is possible that either metabolism was impaired or distribution was abnormal. In patients who develop "on-off" attacks, therefore, unusual pharmacokinetics may prove to be a contributing factor. Having obtained this evidence that "on-off" phenomena are related to excessive plasma concentrations of levodopa, certain practical implications should be considered. When starting patients on levodopa it may be unwise to increase the dose to maximum tolerated levels in all cases. Barbeau (1972) also concluded from clinical observations that "on-off" attacks represent levodopa toxicity, and he has suggested that an arbitrary upper dose limit around 4-0 g a day should be set for routine therapy until further evidence is available.
In addition to preventing attacks there is the problem of managing patients in whom these episodes are established. It is evident that unless the excessive peaks of plasma levodopa can be reduced by more frequent administration of smaller doses the total daily intake of levodopa should be decreased. The addition of peripheral decarboxylase leads to less extreme fluctuations in the plasma concentration of levodopa through the day, but mean plasma concentrations tend to be rather higher so it is not possible to predict how "on-off" phenomena will be affected.
This study was supported by the Medical Research Council.
Introduction
Active chronic hepatitis was first delineated as a distinct entity because of its association with the lupus erythematosus (L.E.) cell (Joske and King, 1955) . Since then several immunological abnormalities have been described but the pathogenesis of this syndrome remains uncertain. The finding of anti-smoothmuscle antibody suggests that humoral immunity could be involved, but the relation between a smooth muscle antigen and the presence of progressive hepatitis has not been adequately explained Doniach, 1972) . Farrow et al. (1971) suggested that the antibody might react with a component of normal liver, but no convincing evidence of in-vivo binding of immunoglobulin has been presented. Immunofluorescent studies on the liver have failed to show any specific change in active chronic hepatitis (Hadziyannis et al., 1969) , and have not provided any evidence to support a significant role for antibody in producing the hepatic changes. Nevertheless, the available evidence could be misleading because some authors have failed to distinguish between untreated cases and those receiving steroids or immunosuppressive therapy. It is known that in glomerulonephritis treatment may substantially affect the amount of immunoglobulin which is found in the glomerulus. The present report describes a distinctive pattern ofimmunoglobulin binding in the liver of three patients with active chronic hepatitis and a high titre of anti-smooth-muscle antibody. (Dawkins and Holborow, 1972) .
Sera from all patients were tested by means of indirect immunofluorescence utilizing a composite block of rat liver, rat kidney, rat stomach, rat heart, and mouse stomach. For routine screening the polyvalent antihuman immunoglobulin conjugate was used, but when antibodies were found these were classed by means of monospecific conjugates.
Patients Studied and Results
The 33 patients included 27 with a variety of conditions ranging from alcoholic hepatitis to porphyria. Only one of these 27 showed anti-smooth-muscle antibody. He was a 50-year-old man with chronic Australia antigenaemia and malarial hepatitis. The biopsies from these 27 cases showed no specific pattern of BRElISH MEDICAL JOURNAL 16 JUNE 1973 staining. In two patients with porphyria the characteristic red autofluorescence of the liver was seen but there was no additional abnormality after direct staining. In the remaining 25 cases there was sometimes some poorly defined staining with and around intrahepatic vessels and ducts. This pattern was not found to be of diagnostic significance.
Six patients had the clinical and histological features of active nic hepatitis. These included liver disease lasting six months or more, jaundice at some stage of the disease, and increased serum levels ofalkaline phosphatase, transaminase, and IgG. All six patients were Australia antigen negative. At some stage of the disease liver biopsies from all showed chronic aggressive hepatitis with or without cirrhosis. None had received steroid or immunosuppressive therapy for six months before biopsy.
Three of these patients did not show anti-smooth-muscle antibody, though one possessed anti-cardiac-muscle antibody. Liver tissue from these three showed no consistent pattern of stining on direct immunofluorescence. The remaining three patients were women aged 16, 18, and 21 years at the onset of their disease. All had IgG antibody to smooth muscle in high titre and one also had antinuclear factor. Biopsies from these three cases showed a distinctive pattern of stang. With polyvalent anihuman immunoglobulin-FITC and with monospecific anti-IgG-FITC there was relatively coarse, linear fluorescence along many hepatic cords and patchy polygonal fluorescence around some individual hepatocytes (figs. 1 and 2). The precise localization of the immunoglobulin was not readily apparent because of the limitations of immunofluorescence, the paucity of material, and the architectural distortion associated with active chronic hepatitis and cirrhosis. The staining, however, appeared to be intercellular rather than actually on the hepatocyte surface. The distinctive linear pattern was "blocked" by pretratment with unconjugated anti-IgG indicating that the deposited material contained IgG. There was no evidence of IgM, IgA, fibrinogen, or complement.
Pretreatment of normal liver biopsy specimens with sera containing the anti-smooth-muscle antibody led to a fine FIG. 2-As fig. 1 , showing linear and pericellular deposition of IgG. (x 450.) polygonal network as described by others but did not completely reproduce the coarser patchy staining found in the present three livers by direct immunofluorescence.
Viable cell staining on the liver of the third case with active chronic hepatitis and high titre anti-smooth-muscle antibody failed to show surface-bound IgG.
Discussion
The present evidence indicates that IgG may be deposited in the liver of some patients with active chronic hepatitis. All three positive cases possessed features in common, being young women who were untreated at the time of biopsy. All three possessed high titres of IgG anti-smooth-muscle antibody and this may indicate that only the antibody-positive patient has hepatic binding of IgG. Since the serum anibody was of the IgG class in all three cases, possibly anti-smooth-muscle antibody itself is bound within the liver. In view of the findings of , the present observations might be interpreted in terms of an antigen which crossreacts with smooth muscle. If this is the case, however, the failure of anti-smooth-muscle antibody completely to reproduce the characteristic pattern in normal livers suggests that the antigen must be altered in some way in association with active chronic hepatitis. One of several alternative explanations would be that the IgG is an antibody directed against, and reacted with, some liver-specific antigen unrelated to smooth muscle. Another possibility is that the IgG reflects the deposition of circulating antigen-antibody complexes. Further speculation is premature until it has been shown that the staining pattern is due to the deposition of a specific antibody and until the relevant antigen has been identified.
Work is in progress to determine the precise significance and diagnostic specificity of the finding of IgG, but it is suggested that direct immunofluorescence should be performed on liver biopsies. Humoral mechanisms may prove to be important in the pathogenesis of at least antibody-positive active chronic hepatitis. Recent evidence favouring the involvement of cellmediated immunity should not be considered in isolation (Miller et al., 1972) .
Chemically they consist of a polypeptide chain to which are attached a large number of oligosaccharide units which surround and protect the protein core from proteolysis. The carbohydrate, therefore, is the most important component in determining the physical, chemical, and biological properties of the molecule. This carbohydrate consists of varying proportions of fucose, mannose, galactose, N-acetylglucosamine, N-acetylgalactosamine, and sialic acid. Endoscopic mucosal biopsy specimens provide a convenient uncontaminated source of mucus, and their carbohydrate composition is almost exclusively contributed by mucus adherent to the epithelial surface or within goblet cells (Brown et al., 1972) . Gas liquid chromatography is capable of analysing the monosaccharide content of the mucous glycoproteins from these small mucosal specimens. Studies were also carried out on first-specimen meconium, which is an abundant source of uncontaminated intestinal secretions containing a large proporion of mucous glycoprotein (D. Fraser and J. R. Clamp, unpublished findings), and this was used for the isolation of reasonable quantities of the two major glycoprotein fractions.
Materials and Methods
Mucosal biopsy speamens were collected at colonoscopy or sigmoidoscopy from normal subjects and from patients with ulcerative colitis, chronic diarrhoea, and infective diarrhoea.
All specimens were taken from a constant anatomical sitenamely, the rectosigmoid junction-using either the Olympus
